Price regulation and generic competition in the pharmaceutical market

Dag Morten Dalen (), Steinar Strøm () and Tonje Haabeth
Additional contact information
Dag Morten Dalen: Norwegian School of Management and the Frisch Centre, Postal: Gaustadalléen 21, N-0349 Oslo, Norway
Tonje Haabeth: University of Oslo and the Frisch Centre, Postal: Department of Economics, University of Oslo, P.O Box 1095 Blindern, N-0317 Oslo, Norway

No 33/2005, Memorandum from Oslo University, Department of Economics

Abstract: In March 2003 the Norwegian government implemented yardstick based price regulation schemes on a selection of drugs experiencing generic competition. The retail price cap, termed “index price”, on a drug (chemical substance) was set equal to the average of the three lowest producer prices on that drug, plus a fixed wholesale and retail margin. This is supposed to lower barriers of entry for generic drugs and to trigger price competition. Using monthly data over the period 1998-2004 for the 6 drugs (chemical entities) included in the index price system, we estimate a structural model enabling us to examine the impact of the reform on both demand and market power. Our results suggest that the index price helped to increase the market shares of generic drugs and succeeded in triggering price competition.

Keywords: Discrete choice; demand for pharmaceuticals; monopolistic competition; evaluation of yardstick based price regulation (search for similar items in EconPapers)
JEL-codes: C35 D43 I18 L11 (search for similar items in EconPapers)
Pages: 26 pages
Date: 2005-11-25
New Economics Papers: this item is included in nep-com, nep-cse, nep-dcm, nep-hea, nep-mic and nep-reg
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sv.uio.no/econ/english/research/unpubli ... 005/Memo-33-2005.pdf (application/pdf)

Related works:
Working Paper: Price regulation and generic competition in the pharmaceutical market (2009)
Journal Article: Price regulation and generic competition in the pharmaceutical market (2006)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hhs:osloec:2005_033

Access Statistics for this paper

More papers in Memorandum from Oslo University, Department of Economics Department of Economics, University of Oslo, P.O Box 1095 Blindern, N-0317 Oslo, Norway. Contact information at EDIRC.
Bibliographic data for series maintained by Mari Strønstad Øverås ().